|Articles|May 16, 2012

Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy

Dr. Singh discusses CVS Caremark's strategies for managing oncology spending.

Surya Singh, MD, Vice President, Medical Benefit Management, CVS Caremark, states that there are a variety of approaches used to stem the rise of costs associated with oncology. However, Dr. Singh point out that there is not a one-size-fits-all approach to doing so.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy

Related Content

Emerging Inhaled IPF Therapies Show Promise: Steven D. Nathan, MD

Expanding Donor Access for ASCT in AML: Karilyn Larkin, MD

Closing the Gap Between Myeloma Science and Access: Doris Hansen, MD

Recognizing Early ILD Symptoms Can Speed Up Diagnosis: Steven D. Nathan, MD

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

Trending on AJMC

Lilly Expands Retatrutide Access Amid Doctor Pushback

Senate Confirms Erica Schwartz as CDC Director After Yearlong Vacancy

CANN Responds to HRSA's Revised 340B Rebate Model Pilot

Infection Remains a Major Burden in Blood Cancers

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Surya Singh, MD, Addresses Ways to Manage Oncology Spending in Specialty Pharmacy

Related Content

Emerging Inhaled IPF Therapies Show Promise: Steven D. Nathan, MD

Expanding Donor Access for ASCT in AML: Karilyn Larkin, MD

Closing the Gap Between Myeloma Science and Access: Doris Hansen, MD

Recognizing Early ILD Symptoms Can Speed Up Diagnosis: Steven D. Nathan, MD

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

Trending on AJMC

Lilly Expands Retatrutide Access Amid Doctor Pushback

Senate Confirms Erica Schwartz as CDC Director After Yearlong Vacancy

CANN Responds to HRSA's Revised 340B Rebate Model Pilot

Infection Remains a Major Burden in Blood Cancers